Search

Displaying results 7121 - 7130 of 10000 in total
  1. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58.

  2. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the … Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone.

  3. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  4. Drug

    GS-100

    go.drugbank.com/drugs/DB18337
    Investigational

    GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence

  5. Drug

    Dofequidar

    go.drugbank.com/drugs/DB14067
    Investigational

    Dofequidar is an antineoplastic agent.

  6. Drug

    Cambritaxestat

    go.drugbank.com/drugs/DB18723
    Investigational

    Cambritaxestat is an autotaxin inhibitor.

  7. Drug

    Excindogen

    go.drugbank.com/drugs/DB18754
    Experimental

    Excindogen is an investigational immunotherapy.

  8. Drug

    Pirodavir

    go.drugbank.com/drugs/DB08012
    Experimental

    Pirodavir is an antipicornavirus agent.

  9. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  10. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter [L1858]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].